Statistics for Lineage Cell Therapeutics (id:163 LCTX)

Valuation metrics

Market cap

167.12M

Enterprise value

135.44M

Trailing P/E (ttm)

-5.00

Forward P/E

-5.90

PEG ratio

-5.90

Price/Sales (ttm)

27.02

Price/Book (mrq)

2.44

Enterprise Value/Revenue

21.89

Enterprise Value/EBITDA

-6.33

Overview

Shares outstanding

188.84M

Float

146.34M

Shares short

15.94M

% Held by insiders

0.00%

% Held by institutions

0.51%

Average volume (10 days)

524.55K

Average volume (90 days)

Price summary

52-Week low

0.56

52-Week high

1.61

52-Week change

-63.33%

Beta

1.28

50-Day moving average

0.89

200-Day moving average

1.02

Dividends and splits

Forward annual dividend rate

1.25

Forward annual dividend yield

2.08

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

January 04th, 2016

Last split factor

2:1

Last split date

October 31th, 1997

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

June 30th, 2024

Profitability

Profit margin

92.50%

Operating margin

-416.69%

Operational effectiveness

Return on assets

-12.86%

Return on equity

-35.04%

Income statement

Revenue (ttm)

0.03

Revenue per share (ttm)

0.03

Quarterly revenue growth (yoy)

Gross profit (ttm)

8.27M

EBITDA

-21,397,000.00

Net income to common (ttm)

-24,187,000.00

Diluted EPS (ttm)

-0.13

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

38.50M

Total cash per share (mrq)

0.20

Total debt (mrq)

2.95M

Total Debt/Equity (mrq)

4.41

Current ratio (mrq)

264.40%

Book value per share (mrq)

0.36

Cash flow

Cash flow statement

-22,015,000.00

Levered free cash flow (LFCF)

-8,912,625.00